-
Maternal serum human placental growth hormone (hPGH) at 11 to 13 weeks of gestation in preeclampsia.
Sifakis S, Akolekar R, Mantas N, Kappou D, Nicolaides KH.
Hypertens Pregnancy 2011;30:74-82. -
Pregenesys pre-eclampsia markers consensus meeting: What do we require from markers, risk assessment and model systems to tailor preventive strategies?
Cetin I, Huppertz B, Burton G, Cuckle H, Gonen R, Lapaire O, Mandia L, Nicolaides K, Redman C, Soothill P, Spencer K, Thilaganathan B, Williams D, Meiri H.
Placenta 2011;32:S4-16. -
Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks.
Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH.
Prenat Diagn 2011;31:66-74. -
Maternal plasma plasminogen activator inhibitor-2 at 11 to 13 Weeks of gestation in hypertensive disorders of pregnancy.
Akolekar R, Cruz JJ, Penco JM, Zhou Y, Nicolaides KH.
Hypertens Pregnancy 2011;30:194-202. -
Maternal serum soluble adhesion molecule levels at 11+0-13+6 weeks and subsequent development of pre-eclampsia.
Parra-Cordero M, Turan OM, Kaur A, Pearson JD, Nicolaides KH.
J Matern Fetal Neonatal Med 2007;20:793-6. -
Placental ABCA1 expression is reduced in primary antiphospholipid syndrome compared to pre-eclampsia and controls.
Albrecht C, Soumian S, Tetlow N, Patel P, Sullivan MH, Lakasing L, Nicolaides K, Williamson C.
Placenta 2007;28:701-8.